HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Mutual Fund Rank
Did you know that Zacks now ranks mutual funds? We've reinvented the way mutual funds are rated.   Try it now.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Top 10 Stocks
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


CNMD: Conmed Cp - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

CONMED CP (NASD)
CNMD 22.37 N/A (N/A%) Vol.  0 N/A ET

Day Low - High N/A - N/A
52wk Low - High 11.56 - 24.43
Avg Volume 138,131
Industry MED/DENTAL-SUPP
Market Cap 645.24 M
Div - Yield 0.00 - 0.00
PE (forward) 17.74
PEG Ratio N/A
Current Year Est. 1.25
EPS Last Year 1.01
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Buy12%
# 2Strong Sell50.23%
# 3Hold14%
# 4Sell3.97%
# 5Hold1.85%
S&P50012.22%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 10/30/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
CONMED CP CNMD PREMIUM
MWI VET SUPPLY MWIV PREMIUM
BIO REFERNC LAB BRLI PREMIUM
INVACARE CORP IVC PREMIUM
See all MED/DENTAL-SUPP Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.25
ABR (Last Week) 2.25
# of Recs in ABR 4
Average Target Price 26.50
Industry Rank by ABR 128 out of 217
Rank in Industry 23 out of 33
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate CNMD?
Buy
Sell
Find out what the Zacks Community
thinks of CNMD at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR CNMD
Zacks Blog: Conmed Surpasses Estimate
Feb 08, 2010
Zacks Blog: Medical Devices Stock Review - Feb. 2010
Feb 01, 2010
Zacks Analyst Interviews: Medical Devices Stock Review - Feb. 2010
Feb 01, 2010
Industry Outlook: Medical Devices Stock Review - Feb. '10
Feb 01, 2010
Industry Outlook: Medical Devices Stock Review - Feb. 2010
Feb 01, 2010
Zacks Blog: Stryker Reports Preliminary Results
Jan 14, 2010
Zacks Blog: Stryker Completes Acquisition
Jan 04, 2010
Zacks Blog: Stryker’s New Share Repurchases
Dec 10, 2009
More Zacks Commentary
NEWS
CONMED Guides In-line
Feb 04, 2010
CONMED Corporation Announces Fourth Quarter and Full Year 2009Results
Feb 04, 2010
SmarTrend's Candlestick Scanner Detects Bullish Engulfing Pattern for Conmed (CNMD)
Feb 02, 2010
PolyOne Receives Supplier Excellence Award from CONMED Linvatec
Jan 19, 2010
CONMED Corporation to Announce Fourth Quarter 2009 Financial Resultson February 4, 2010
Jan 07, 2010
CONMED Corporation Will Participate in Two Investor Conferences
Jan 05, 2010
Conmed Up 35.6% Since SmarTrend's Buy Recommendation
Dec 15, 2009
Conmed Up 30.3% Since SmarTrend's Buy Recommendation
Dec 08, 2009
More News
EARNINGS ESTIMATES
  This Quarter
03/2010
Next Quarter
06/2010
This Year
12/2010
Next Year
12/2011
Average Estimate 0.26 0.30 1.25 1.54
Number of Estimates 3 3 3 3
Low Estimates 0.24 0.29 1.22 1.37
High Estimate 0.28 0.31 1.29 1.77
Year Ago EPS 0.19 0.17 1.00 1.25
EPS Growth 35.09% 78.43% 25.00% 23.20%

More Estimates

COMPANY DESCRIPTION
CONMED Corporation is a medical technology company specializing in instruments and implants for arthroscopic sports medicine, and powered surgical instruments, such as drills and saws, for orthopaedic, ENT and neurosurgery. The company is also a leading developer, manufacturer and supplier of advanced medical devices, including electrosurgical systems, electrodes for heart monitoring. The company's products are used in a variety of clinical settings, such as operating rooms, surgery centers, physicians' offices and critical care areas of hospitals.

Full Company Report
FINANCIALS
EPS TTM 1.01
Sales 694.74
Net Income 12.14
Price/Earnings 21.95
Price/Book 1.12
Price/Cash Flow 19.4
Price/Sales .93


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2010 Zacks Investment Research